InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on InspireMD in a report on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price for the company.

InspireMD Stock Performance

Shares of NSPR opened at $2.76 on Tuesday. The stock has a 50 day simple moving average of $2.82 and a 200 day simple moving average of $2.72. InspireMD has a 52-week low of $1.81 and a 52-week high of $3.42. The firm has a market capitalization of $71.98 million, a PE ratio of -3.68 and a beta of 0.99.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The company had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter in the prior year, the company earned ($0.15) earnings per share. Equities research analysts predict that InspireMD will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently bought a new position in InspireMD stock. Parkman Healthcare Partners LLC bought a new position in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned approximately 0.42% of InspireMD as of its most recent filing with the Securities & Exchange Commission. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.